GILD · Gilead Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B |
| Cost of Revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B |
| Gross Profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B |
| R&D | $5.80B | $5.91B | $5.72B | $4.98B | $5.36B | $5.04B |
| SG&A | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | $5.15B |
| Total Operating Expenses | $19.42B | $27.09B | $19.51B | $19.95B | $17.39B | $20.62B |
| D&A | $370.00M | $381.00M | $354.00M | $323.00M | $329.00M | $288.00M |
| Operating Income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B |
| Interest Expense | $1.02B | $977.00M | $944.00M | $935.00M | $1.00B | $984.00M |
| Income Tax | $1.29B | $211.00M | $1.25B | $1.25B | $2.08B | $1.58B |
| Net Income | $8.51B | $480.00M | $5.67B | $4.59B | $6.22B | $123.00M |
| EPS - Basic | $6.84 | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 |
| EPS - Diluted | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.56B | $9.99B | $6.08B | $5.41B | $5.34B | $6.00B |
| Accounts Receivable | $4.91B | $4.42B | $4.66B | $4.78B | $4.49B | $4.89B |
| Inventory | $1.77B | $1.71B | $1.79B | $1.51B | $1.62B | $1.68B |
| Accounts Payable | $715.00M | $833.00M | $550.00M | $905.00M | $705.00M | $844.00M |
| Current Assets | $18.34B | $19.17B | $16.09B | $14.44B | $14.77B | $16.00B |
| Total Assets | $59.02B | $58.99B | $62.13B | $63.17B | $67.95B | $68.41B |
| Current Liabilities | $11.81B | $12.00B | $11.28B | $11.24B | $11.61B | $11.40B |
| Long-term Debt | $22.13B | $24.90B | $23.19B | $22.96B | $25.18B | $28.64B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $22.70B | $19.33B | $22.83B | $21.24B | $21.07B | $18.20B |
| Retained Earnings | $13.73B | $11.50B | $16.30B | $15.69B | $16.32B | $14.38B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B | $8.17B |
| Investing Cash Flow | ($4.79B) | ($3.45B) | ($2.27B) | ($2.47B) | ($3.13B) | ($14.62B) |
| Financing Cash Flow | ($7.75B) | ($3.43B) | ($5.13B) | ($6.47B) | ($8.88B) | $770.00M |
| CapEx | $563.00M | $523.00M | $585.00M | $728.00M | $579.00M | $650.00M |
| Free Cash Flow | $9.46B | $10.30B | $7.42B | $8.34B | $10.80B | $7.52B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% |
| Operating margin | 34.0% | 5.8% | 28.0% | 26.9% | 36.3% | 16.5% |
| EBITDA margin | 35.3% | 7.1% | 29.4% | 28.1% | 37.5% | 17.7% |
| Net margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% |
| Free cash flow margin | 32.1% | 35.8% | 27.4% | 30.6% | 39.6% | 30.5% |
| FCF / Net income | 1.11 | 21.47 | 1.31 | 1.82 | 1.74 | 61.12 |
| R&D / Revenue | 19.7% | 20.5% | 21.1% | 18.2% | 19.6% | 20.4% |
| SG&A / Revenue | 19.6% | 21.2% | 22.5% | 20.8% | 19.2% | 20.9% |
| Effective tax rate | 13.1% | 30.5% | 18.0% | 21.4% | 25.0% | 92.8% |
| Return on assets | 14.4% | 0.8% | 9.1% | 7.3% | 9.2% | 0.2% |
| Return on equity | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% | 0.7% |
| Return on invested capital | 19.4% | 2.6% | 13.5% | 13.0% | 16.1% | 4.3% |
| Liquidity | ||||||
| Current ratio | 1.55 | 1.60 | 1.43 | 1.29 | 1.27 | 1.40 |
| Quick ratio | 1.40 | 1.45 | 1.27 | 1.15 | 1.13 | 1.26 |
| Cash ratio | 0.64 | 0.83 | 0.54 | 0.48 | 0.46 | 0.53 |
| Leverage | ||||||
| Debt / Equity | 0.97 | 1.29 | 1.02 | 1.08 | 1.20 | 1.57 |
| Debt / Assets | 0.37 | 0.42 | 0.37 | 0.36 | 0.37 | 0.42 |
| Debt / EBITDA | 2.13 | 12.19 | 2.91 | 3.00 | 2.46 | 6.57 |
| Interest coverage | 9.8x | 1.7x | 8.1x | 7.8x | 9.9x | 4.1x |
| Equity multiplier | 2.60 | 3.05 | 2.72 | 2.97 | 3.23 | 3.76 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.50 | 0.49 | 0.44 | 0.43 | 0.40 | 0.36 |
| Inventory turnover | 3.51 | 3.66 | 3.64 | 3.75 | 4.08 | 2.72 |
| Days sales outstanding | 61d | 56d | 63d | 64d | 60d | 72d |
| Days inventory outstanding | 104d | 100d | 100d | 97d | 89d | 134d |
| Days payable outstanding | 42d | 49d | 31d | 58d | 39d | 67d |
| Cash conversion cycle | 123d | 107d | 132d | 103d | 111d | 139d |
| Valuation | ||||||
| P / E | 18.1x | 243.1x | 18.0x | 23.6x | 14.7x | 582.6x |
| P / B | 6.8x | 6.0x | 4.5x | 5.1x | 4.3x | 4.0x |
| P / S | 5.2x | 4.0x | 3.8x | 4.0x | 3.4x | 3.0x |
| EV / EBITDA | 16.2x | 64.0x | 15.0x | 16.4x | 10.9x | 22.1x |
| Growth | ||||||
| Revenue growth (YoY) | 2.4% | 6.0% | -0.6% | -0.1% | 10.6% | 10.0% |
| Revenue CAGR (3y) | 2.6% | 1.7% | 3.2% | 6.7% | -3.5% | -1.8% |
| Revenue CAGR (5y) | 3.6% | 5.1% | -2.3% | 0.9% | -2.1% | -5.4% |
| Gross profit growth (YoY) | 3.1% | 9.1% | -4.7% | 4.4% | 2.9% | 13.2% |
| Operating income growth (YoY) | 503.0% | -78.1% | 3.8% | -26.1% | 143.6% | -5.0% |
| Net income growth (YoY) | 1672.9% | -91.5% | 23.4% | -26.2% | 4961.0% | -97.7% |
| EPS growth (YoY) | 1684.2% | -91.6% | 23.6% | -26.2% | 4830.0% | -97.6% |
| EPS CAGR (3y) | 23.0% | -57.4% | 255.7% | -4.8% | 5.7% | -69.5% |
| EPS CAGR (5y) | 132.4% | -38.2% | 1.5% | 0.7% | -13.1% | -61.6% |
| FCF growth (YoY) | -8.2% | 38.9% | -11.1% | -22.8% | 43.7% | -9.6% |
| FCF CAGR (5y) | 4.7% | 4.4% | -0.1% | -5.9% | -7.5% | -17.4% |
| Book value growth (YoY) | 17.4% | -15.3% | 7.5% | 0.8% | 15.8% | -19.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$71.35B totalProduct$28.91B · 40.5%
HIVProduct Sales$16.90B · 23.7%
HIVProducts Biktarvy$11.47B · 16.1%
HIVProducts Descovy$2.56B · 3.6%
Oncology Product$1.63B · 2.3%
Liver Disease$1.62B · 2.3%
HIVProducts Genvoya$1.28B · 1.8%
HIVProducts Odefsey$881.00M · 1.2%
Trodelvy$877.00M · 1.2%
Cell Therapy Products Total Cell Therapy Product Sales$748.00M · 1.0%
Liver Disease Products Sofosbuvir Velpatasvir$636.00M · 0.9%
Other Products Yescarta$595.00M · 0.8%
Royalty Contract And Other$527.00M · 0.7%
Liver Disease Products Vemlidy$507.00M · 0.7%
Liver Disease Products Other Liver Disease$476.00M · 0.7%
Veklury$470.00M · 0.7%
HIVProducts Symtuza Revenue Share$363.00M · 0.5%
HIVProducts Other HIV$352.00M · 0.5%
Other Products Total Other Product Sales$197.00M · 0.3%
Other Products Other$177.00M · 0.2%
Cell Therapy Products Tecartus$153.00M · 0.2%
Other Products Am Bisome$20.00M · 0.0%
Geographic
$29.44B totalUS$20.88B · 70.9%
Europe$5.06B · 17.2%
Rest Of World$3.50B · 11.9%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing GILEAD SCIENCES against the 5 most active filers in the same SIC group.
Dividends
$3.19/share trailing 12 months · +2.9% YoY
| Ex-date | Per share |
|---|---|
| Mar 13, 2026 | $0.8200 |
| Dec 15, 2025 | $0.7900 |
| Sep 15, 2025 | $0.7900 |
| Jun 13, 2025 | $0.7900 |
| Mar 14, 2025 | $0.7900 |
| Dec 13, 2024 | $0.7700 |
| Sep 13, 2024 | $0.7700 |
| Jun 14, 2024 | $0.7700 |
| Mar 14, 2024 | $0.7700 |
| Dec 14, 2023 | $0.7500 |
| Sep 14, 2023 | $0.7500 |
| Jun 14, 2023 | $0.7500 |
| Mar 14, 2023 | $0.7500 |
| Dec 14, 2022 | $0.7300 |
| Sep 14, 2022 | $0.7300 |
| Jun 14, 2022 | $0.7300 |
| Mar 14, 2022 | $0.7300 |
| Dec 14, 2021 | $0.7100 |
| Sep 14, 2021 | $0.7100 |
| Jun 14, 2021 | $0.7100 |
| Mar 12, 2021 | $0.7100 |
| Dec 14, 2020 | $0.6800 |
| Sep 14, 2020 | $0.6800 |
| Jun 11, 2020 | $0.6800 |